白云山:控股子公司广州白云山天心制药股份有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》,注射用头孢哌酮钠舒巴坦钠(1.0g、1.5g、2.0g)和克林霉素磷酸酯注射液(2ml:0.3g、4ml:0.6g)已通过仿制药质量和疗效一致性评价。2024年天心制药注射用头孢哌酮钠舒巴坦钠(1.0g、1.5g、2.0g)的销售收入为人民币1589.7万元,克林霉素磷酸酯注射液(2ml:...
Source Link白云山:控股子公司广州白云山天心制药股份有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》,注射用头孢哌酮钠舒巴坦钠(1.0g、1.5g、2.0g)和克林霉素磷酸酯注射液(2ml:0.3g、4ml:0.6g)已通过仿制药质量和疗效一致性评价。2024年天心制药注射用头孢哌酮钠舒巴坦钠(1.0g、1.5g、2.0g)的销售收入为人民币1589.7万元,克林霉素磷酸酯注射液(2ml:...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.